Fifty percent in the abatacept group versus 22% in the placebo group reached the primary endpoint at week 12 which was the obtainment of a CRP-PMR-AS ≤ 10, without GC or rescue treatment; however, the difference did not reach statistical significance ( p = 0.07) [ 89 ].
1
0.0700
0.0700